Key Takeaways JNJ stock stayed above 50- and 200-day SMAs for 8 months, signaling sustained bullish momentum.J&'s growth is driven by Innovative Medicine strength, new drugs, and R&D and M&A spend.JNJ faces Stelara patent loss, China headwinds, and 74,000 talc lawsuits, impacting future outlook.Johnson & Johnson’s (JNJ) stock has remained firmly above its 50-day and 200-day simple moving averages (SMAs) for more than eight months, dating back to mid-July 2025, reflecting sustained investor confidence. Notab ...

Quick Read iShares U.S. Pharmaceuticals ETF (IHE) has 46.8% of its $1.1B portfolio concentrated in Johnson & Johnson (JNJ), up 14% year-to-date on strong DARZALEX sales of $3.90B, and Eli Lilly (LLY), down 15% year-to-date despite Mounjaro hitting $7.41B in Q4 2025 revenue. The fund itself is flat year-to-date, down 0.5%, reflecting opposing performance between its two dominant holdings facing pricing pressure and manufacturing constraints. The Trump administration’s aggressive drug pricing reform thro ...

Last Wednesday , Johnson & Johnson ( JNJ ) announced that the FDA had approved Icotyde, a once-daily oral peptide for the treatment of plaque psoriasis. This drug selectively blocks the interleukin-23 receptor (IL-23) and was a joint discovery withBrendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employm ...

Last Wednesday , Johnson & Johnson ( JNJ ) announced that the FDA had approved Icotyde, a once-daily oral peptide for the treatment of plaque psoriasis. This drug selectively blocks the interleukin-23 receptor (IL-23) and was a joint discovery withBrendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employm ...

Johnson & Johnson (NYSE:JNJ) ranks among the best most active stocks to buy right now. On March 13, Johnson & Johnson (NYSE:JNJ) revealed results from a Phase 1 study of an innovative intravesical drug-releasing mechanism with erdafitinib (Erda-iDRS) in patients with non-muscle-invasive bladder cancer who had specific fibroblast growth factor receptor mutations. Pixabay/Public Domain According to the company, the trial met its major safety goals. The intermediate-risk sample of 62 patients had an 89% co ...

Core Insights - TuHURA Biosciences has appointed Dr. Craig L. Tendler as the leader of its VISTA Program in AML and other blood-related cancers, while he continues his role on the Board of Directors [1][2] - Dr. Tendler brings over 29 years of experience in drug development, having coordinated over 30 oncology regulatory approvals and 15 new medical entity approvals, contributing to more than $16 billion in global sales from multiple myeloma treatments [1][2] - The company is focused on developing TBS-2025, a VISTA inhibiting antibody, which is expected to address immunosuppressive roles in AML, particularly in NPM1 mutated cases [2][6] Company Overview - TuHURA Biosciences, Inc. is a Phase 3 immuno-oncology company that develops novel therapeutics aimed at overcoming resistance to cancer immunotherapy [4] - The company’s lead product, IFx-2.0, is designed to counter primary resistance to checkpoint inhibitors and is currently undergoing a Phase 3 trial in combination with Keytruda® for advanced Merkel Cell Carcinoma [5] - TuHURA acquired TBS-2025 through a merger with Kineta Inc. and is advancing it into Phase 2 development for mutNPM1 r/r AML [6] Leadership and Experience - Dr. Tendler previously served as Vice President of Oncology Clinical Development at Johnson & Johnson, where he was instrumental in securing global approvals for several oncology treatments [2][3] - His experience includes leading clinical diligence teams for significant acquisitions and co-development agreements in the oncology sector [2][3] - Dr. Tendler has also held academic positions and has been involved in various cancer research initiatives, enhancing his expertise in the field [3]

Core Viewpoint - Johnson & Johnson received FDA approval for ICOTYDE, an oral treatment for moderate to severe plaque psoriasis, which is seen as a positive development despite the stock's recent decline [1]. Group 1: Company Overview - Johnson & Johnson develops and sells healthcare products, including pharmaceuticals and medical technologies, with a focus on immunology, oncology, neuroscience, cardiovascular care, and infectious diseases [2]. Group 2: Market Reaction - Despite the positive news regarding FDA approval, the stock finished down 0.35% in a challenging market session, indicating that broader market conditions may have overshadowed the company's announcement [1]. - The current market environment is described as a "terrible, horrible, no good, very bad day," suggesting that such conditions may create buying opportunities for investors in Johnson & Johnson [1].

Group 1 - The primary goal of the "High Income DIY Portfolios" service is to provide high income with low risk and capital preservation for DIY investors [1] - The service offers six different portfolios tailored for various income-seeking investors, including retirees or near-retirees [1] - The portfolios include two High-Income portfolios, a Dividend Growth Investing (DGI) portfolio, a conservative strategy for 401K accounts, a Sector-Rotation strategy, and a High-Growth portfolio [1] Group 2 - The "High Income DIY Portfolios" service includes a total of 10 model portfolios with varying income targets and risk levels, along with buy and sell alerts and live chat support [2] - The investment approach focuses on dividend-growing stocks with a long-term horizon, aiming for lower drawdowns and sustainable yields [2] - The service is designed to help investors create stable, long-term passive income [2]

Core Insights - Protagonist Therapeutics (PTGX) shares have increased nearly 7% following the FDA approval of icotrokinra, developed in partnership with Johnson & Johnson (JNJ), for treating moderate-to-severe plaque psoriasis in patients aged 12 and older [1][6] FDA Approval and Product Details - Icotrokinra, marketed as Icotyde in the U.S., is the first targeted oral peptide designed to inhibit the IL-23 receptor [2][4] - The FDA approval was supported by data from four phase III studies within the ICONIC program, demonstrating significant skin clearance and a favorable safety profile [4] Financial Implications - Protagonist will receive a $50 million milestone payment from JNJ, with potential for up to $580 million more in regulatory and sales-based milestones [6][7] - Protagonist is entitled to tiered royalties on global net sales, ranging from 6% to 10%, with an average of approximately 7.25% at $4 billion in annual sales [7] Market Potential - JNJ believes Icotyde has the potential to revolutionize plaque psoriasis treatment as a once-daily oral alternative to existing injectables [8] - Icotyde is also being evaluated for other indications, including psoriatic arthritis and inflammatory bowel diseases, indicating broader market potential [9]

This week's biotech landscape witnessed key FDA approvals, rejections, NDA resubmissions, merger terminations, trial discontinuations, and clinical trial data readouts across therapeutic areas such as Turner Syndrome, Late-Line Colorectal Cancer, Obesity, and Type 1 Diabetes. Let us unpack the key developments and milestones in the biotech space this week. FDA and EU Approvals & Rejections GSK's Lynavoy Wins FDA Approval for Cholestatic Pruritus in PBC GSK plc (GSK), secured for Lynavoy, the first U.S. tre ...